AU Patent

AU2014280956B2 — Chemically modified small molecules

Assigned to Nektar Therapeutics · Expires 2016-09-22 · 10y expired

What this patent protects

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition, A conjugate of the invention, when administered by any of a number of administra…

USPTO Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition, A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014280956B2
Jurisdiction
AU
Classification
—
Expires
2016-09-22
Drug substance claim
No
Drug product claim
No
Assignee
Nektar Therapeutics
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.